These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31250043)

  • 1. Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy.
    Bolland MJ; Horne AM; Briggs SE; Thomas MG; Reid IR; Gamble GD; Grey A
    Calcif Tissue Int; 2019 Oct; 105(4):423-429. PubMed ID: 31250043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years.
    Kwak MK; Lee EJ; Park JW; Park SY; Kim B-; Kim TH; Suh K; Koh J-; Lee SH; Byun D-
    Osteoporos Int; 2019 Jul; 30(7):1501-1510. PubMed ID: 30915506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
    Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
    Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
    Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
    Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection.
    Sharma A; Flom PL; Weedon J; Klein RS
    AIDS; 2010 Sep; 24(15):2337-45. PubMed ID: 20683316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous antiretroviral therapy decreases bone mineral density.
    Grund B; Peng G; Gibert CL; Hoy JF; Isaksson RL; Shlay JC; Martinez E; Reiss P; Visnegarwala F; Carr AD;
    AIDS; 2009 Jul; 23(12):1519-29. PubMed ID: 19531929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
    Assoumou L; Katlama C; Viard JP; Bentata M; Simon A; Roux C; Kolta S; Costagliola D; Rozenberg S;
    AIDS; 2013 Sep; 27(15):2425-30. PubMed ID: 24029735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.
    Escota GV; Mondy K; Bush T; Conley L; Brooks JT; Önen N; Patel P; Kojic EM; Henry K; Hammer J; Wood KC; Lichtenstein KA; Overton ET
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):59-67. PubMed ID: 26366785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease.
    Kooij KW; Wit FW; Bisschop PH; Schouten J; Stolte IG; Prins M; van der Valk M; Prins JM; van Eck-Smit BL; Lips P; Reiss P;
    J Infect Dis; 2015 Feb; 211(4):539-48. PubMed ID: 25180239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
    Bruera D; Luna N; David DO; Bergoglio LM; Zamudio J
    AIDS; 2003 Sep; 17(13):1917-23. PubMed ID: 12960824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):191-7. PubMed ID: 16886959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and risk factors for bone mineral density changes in antiretroviral therapy-naive human immunodeficiency virus-infected adults: a Chinese cohort study.
    Zeng YQ; Xiao J; Li CL; Wang Y; Zhang L; Pang XL; Wang D; Du J; Zhao HX
    Chin Med J (Engl); 2020 Dec; 133(24):2940-2946. PubMed ID: 33278100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy.
    Carr A; Grund B; Schwartz AV; Avihingsanon A; Badal-Faesen S; Bernadino JI; Estrada V; La Rosa A; Mallon P; Pujari S; White D; Wyman Engen N; Ensrud K; Hoy JF;
    HIV Med; 2020 Jan; 21(1):64-70. PubMed ID: 31642586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative contribution of HIV infection, demographics and body mass index to bone mineral density.
    Cotter AG; Sabin CA; Simelane S; Macken A; Kavanagh E; Brady JJ; McCarthy G; Compston J; Mallon PW;
    AIDS; 2014 Sep; 28(14):2051-60. PubMed ID: 25265073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
    Hoy JF; Grund B; Roediger M; Schwartz AV; Shepherd J; Avihingsanon A; Badal-Faesen S; de Wit S; Jacoby S; La Rosa A; Pujari S; Schechter M; White D; Engen NW; Ensrud K; Aagaard PD; Carr A;
    J Bone Miner Res; 2017 Sep; 32(9):1945-1955. PubMed ID: 28650589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.